← All Conditions ← Cancer Overview

Multiple Myeloma

★ CMTO Exam Focus

Multiple myeloma ("marrow tumor") is a hematologic cancer of maturing B cells (plasma cells) in bone marrow. It is the most common form of myeloma, producing tumors at several skeletal sites simultaneously. The cancerous cells actively dismantle bone tissue via osteoclast signaling, creating extreme fracture risk, and produce nonfunctioning antibodies (M-proteins) whose fragments (Bence Jones proteins) are directly toxic to renal tubules. Bone fragility is the primary safety concern for massage therapy.

Pathophysiology

  • Cancerous plasma cells secrete cytokines that signal osteoclasts to dismantle bone, creating lytic ("punched-out") lesions in spine, pelvis, ribs, and skull
  • Produce massive amounts of nonfunctioning M-proteinsM-Spike on protein electrophoresis is the hallmark diagnostic finding
  • Bence Jones proteins (M-protein fragments) pass into kidneys and are directly toxic to renal tubules, potentially causing kidney failure
  • Interferes with normal blood cell production: anemia, thrombocytopenia, reduced infection resistance
  • Hypercalcemia: Excessive calcium released from dismantled bone causes confusion, nausea, and further kidney damage
  • Almost exclusively affects those over 50. Twice as common among African Americans

Signs and Symptoms

Hallmark Indicators

  • Deep bone pain, particularly back, ribs, or hips
  • Spontaneous fractures with little or no trauma (pathologic fractures)
  • Anemia: profound fatigue, weakness, pallor
  • Decreased urine output or signs of kidney failure
  • Recurrent bacterial infections
  • Lower extremity weakness

Red Flags and Rule-Outs

  • Spontaneous fractures with minimal trauma: Extreme bone fragility — contraindicated for any forceful technique
  • Deep bone tenderness on palpation of sternum, spine, or ribs: Reflects marrow expansion and subperiosteal infiltration
  • Decreased urine output or confusion: May indicate hypercalcemia or renal failure — urgent medical concern
  • Bence Jones proteins in urine: Definitive indicator of myeloma-related renal risk
  • Multiple lytic ("punched-out") lesions on imaging: Characteristic of myeloma

MT Considerations

  • Fracture risk is the primary safety concern: Extreme bone fragility requires highly conservative pressure and positioning. Avoid deep pressure, joint traction, and high-velocity movements
  • Platelet precaution: If platelets are low, use extremely light pressure comparable to applying lotion
  • Local contraindications: No intrusive techniques or deep pressure over known tumor sites or bone lesions
  • Positioning: Prone may cause pain due to fragile ribs and vertebrae. Use bolstering alternatives
  • Clinical integration: Coordinate with medical team to monitor kidney stability and treatment complications
  • Amyloidosis link: Myeloma is a common precursor to secondary amyloidosis (inflammatory proteins accumulating in heart or lungs)
  • Treatment side effects: See chemotherapy and radiation-therapy

CMTO Exam Relevance

  • Lytic ("punched-out") lesions on bone imaging are characteristic of myeloma
  • Bence Jones proteins in urine indicate myeloma-related renal risk
  • M-Spike on protein electrophoresis is the hallmark diagnostic finding
  • Hypercalcemia from bone destruction causes confusion, nausea, and kidney damage
  • Myeloma is a common precursor to secondary amyloidosis
  • Almost exclusively affects those over 50. Twice as common among African Americans

Key Takeaways

  • Multiple myeloma actively dismantles bone via osteoclast signaling, creating extreme fracture risk at multiple sites simultaneously
  • Bence Jones proteins are directly toxic to renal tubules — the hallmark of myeloma-related kidney damage
  • Pressure must be extremely conservative. Avoid deep techniques, joint traction, and forceful movements over fragile bone
  • Hypercalcemia from bone destruction is a dangerous systemic complication
  • Coordinate with the healthcare team to monitor kidney stability and treatment complications

Sources

  • Rattray, F., & Ludwig, L. (2000). Clinical massage therapy: Understanding, assessing and treating over 70 conditions. Talus Incorporated.
  • Werner, R. (2016). A massage therapist's guide to pathology (6th ed.). Books of Discovery.
  • Norris, T. L. (2019). Porth's essentials of pathophysiology (5th ed.). Wolters Kluwer.